Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19
BEDMINSTER, N.J., Jan. 15, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with The Wistar Institute, an international leader in biomedical research, to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms.
PAD4 is an enzyme that catalyzes conversion of arginine to citrulline in proteins, including histones and is highly expressed in neutrophils. Histone citrullination has been implicated in Neutrophil Extracellular Trap (NET) formation and accumulating evidence suggests that NETs may be linked to the severity of COVID-19, as their formation is a result of pro-inflammatory cytokine release syndrome (CRS), or cytokine storms, produced by the body's immune response to the SARS-CoV-2 virus. Cytokine storms are implicated in the development of acute respiratory distress syndrome (ARDS), which is the leading cause of death in patients infected with COVID-19.
"We are very pleased to announce our collaboration with the renowned Wistar Institute," said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics. "Even with COVID-19 vaccines on the horizon, we know its wrath will persist for some time to come and the need to reduce its death toll remains critical. Beyond COVID-19, understanding the potential of PAD4 inhibitors to address aberrant NET formation will be important due to their role in the pathogenesis of many disease states beyond viral infections."
"This collaboration with Jubilant Therapeutics will further advance our comprehensive research efforts to find therapeutics to diminish cytokine storms and decrease COVID-19 symptom gravity," said Yulia Nefedova, M.D., Ph.D., associate professor in the Immunology, Microenvironment & Metastasis Program at The Wistar Institute. "It is our hope that Jubilant Therapeutics' inhibitors will prove successful in blocking NET formation to this end."
About The Wistar Institute
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. Wistar's business development team is advancing Wistar science and technology development through creative partnerships. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.
About Jubilant Therapeutics
Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Its advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations. The Company's entrepreneurial-minded leadership and scientific teams strive for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Life Sciences Limited's value chain and shared services. Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members. For more information, please visit www.jubilanttx.com or follow us on Twitter @JubilantTx and LinkedIn.
SOURCE Jubilant Therapeutics Inc.
Share this article